Literature DB >> 6171586

Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps.

D G Marsh, P S Norman, M Roebber, L M Lichtenstein.   

Abstract

We have devised a new process for modifying heat-labile allergens, which employs a sequential "two-step" incubation at temperatures of 10 degree C and 30 degree to 32 degree C. This process was found to produce effective ragweed "allergoids" with low allergenicity and good immunogenicity, which makes them useful for the therapy of allergic humans. Modification with formaldehyde produced derivatives ("formallergoids") that were about 10-fold less allergenic in allergic humans (as measured by leukocyte histamine-release assay), and similarly or more immunogenic in guinea pigs, than glutaraldehyde-modified allergens ("glutarallergoids"). Further analysis by RAST inhibition showed that a ragweed formallergoid was sixfold less reactive than a glutarallergoid with a pool of human IgE antibodies. However, the formallergoid had retained the ability to induce a wide array of antibodies against native ragweed antigens, since rabbit anti-formallergoid serum was able to recognize at least 12 different ragweed antigens, including AgE. Gel-filtration experiments showed that both the formallergoid and glutarallergoid materials contained polymers having apparent molecular weights distributed around 260,000 and 230,000 daltons, respectively (approximate range 30,000 to 900,000 daltons). Our studies provide the immunochemical basis for the use of these allergoids in the therapy of allergic humans.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6171586     DOI: 10.1016/0091-6749(81)90199-8

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Standardized extracts modified allergens--allergoids.

Authors:  H J Maasch; D G Marsh
Journal:  Clin Rev Allergy       Date:  1987-02

Review 2.  New strategies for allergen T cell epitope identification: going beyond IgE.

Authors:  Véronique Schulten; Bjoern Peters; Alessandro Sette
Journal:  Int Arch Allergy Immunol       Date:  2014-11-15       Impact factor: 2.749

Review 3.  Recombinant allergens: the present and the future.

Authors:  Marek Jutel; Katarzyna Solarewicz-Madejek; Sylwia Smolinska
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 4.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 5.  Allergen immunotherapy with cat allergen peptides.

Authors:  A Barry Kay; Mark Larché
Journal:  Springer Semin Immunopathol       Date:  2003-09-30

6.  Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy.

Authors:  H Henmar; G Lund; L Lund; A Petersen; P A Würtzen
Journal:  Clin Exp Immunol       Date:  2008-07-18       Impact factor: 4.330

Review 7.  Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy.

Authors:  S R Prickett; J M Rolland; R E O'Hehir
Journal:  Clin Exp Allergy       Date:  2015-06       Impact factor: 5.018

Review 8.  Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials.

Authors:  Martin Himly; Robert Mills-Goodlet; Mark Geppert; Albert Duschl
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

9.  13-year overview of serious adverse drug reactions following subcutaneous specific immunotherapy with a chemically modified allergen preparation.

Authors:  Andreas Distler; Debbie Pappelendam
Journal:  Allergo J Int       Date:  2015-12-17

Review 10.  Past, present, and future of allergen immunotherapy vaccines.

Authors:  Yulia Dorofeeva; Igor Shilovskiy; Inna Tulaeva; Margarete Focke-Tejkl; Sabine Flicker; Dmitriy Kudlay; Musa Khaitov; Antonina Karsonova; Ksenja Riabova; Alexander Karaulov; Roman Khanferyan; Winfried F Pickl; Thomas Wekerle; Rudolf Valenta
Journal:  Allergy       Date:  2020-04-29       Impact factor: 13.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.